Malignant testicular germ cell tumor
diseaseOn this page
Also known as malignant germ cell neoplasm of testismalignant germ cell neoplasm of the testismalignant germ cell tumor of testismalignant germ cell tumor of the testismalignant germ cell tumour of testismalignant germ cell tumour of the testismalignant testicular germ cell neoplasmtesticular ca. (no germ/tropho.)testicular cancertesticular cancer (excluding germ cell or trophoblastic cancer)testicular germ cell cancer
Summary
Malignant testicular germ cell tumor (MONDO:0003510) is a cancer (an umbrella term covering 6 Mondo subtypes) and 113 clinical trials. Top therapeutic interventions include cisplatin, 2-mercaptoethanesulfonic acid, and bleomycin sulfate. A subtype of testicular cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 6 Mondo subtypes
- Clinical trials: 113
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | malignant testicular germ cell tumor |
| Mondo ID | MONDO:0003510 |
| DOID | DOID:5556 |
| NCIT | C9063 |
| SNOMED CT | 713646001 |
| UMLS | C0855197 |
| MedGen | 163616 |
| GARD | 0023539 |
| Anatomy (UBERON) | UBERON:0000473 |
| Is cancer (heuristic) | yes |
Also known as: malignant germ cell neoplasm of testis · malignant germ cell neoplasm of the testis · malignant germ cell tumor of testis · malignant germ cell tumor of the testis · malignant germ cell tumour of testis · malignant germ cell tumour of the testis · malignant testicular germ cell neoplasm · malignant testicular germ cell tumor · testicular ca. (no germ/tropho.) · testicular cancer · testicular cancer (excluding germ cell or trophoblastic cancer) · testicular germ cell cancer
Disease family
This is a subtype of testicular cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › male reproductive organ cancer › testicular cancer › malignant testicular germ cell tumor
Related subtypes (10): malignant Sertoli-Leydig cell tumor, testicular lymphoma, malignant tumor of undescended testis, testicular leukemia, rete testis adenocarcinoma, seminal vesicle adenocarcinoma, testicular gonadoblastoma, testis sarcoma, malignant testicular Leydig cell tumor, paratesticular adenocarcinoma
Subtypes (6): mixed testicular germ cell cancer, testicular non-seminomatous germ cell cancer, testicular seminoma, testis refractory cancer, testis polyembryoma, malignant teratoma of testis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 113.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 70 |
| PHASE2 | 22 |
| PHASE1 | 13 |
| PHASE3 | 3 |
| PHASE1/PHASE2 | 3 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01641172 | PHASE4 | COMPLETED | Taste, Smell and Chemotherapy (TASTY) |
| NCT06593665 | PHASE3 | RECRUITING | Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection. |
| NCT00053352 | PHASE3 | COMPLETED | Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors |
| NCT01305200 | PHASE3 | COMPLETED | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant |
| NCT02991209 | PHASE2/PHASE3 | COMPLETED | Study of Testosterone vs Placebo in Testicular Cancer Survivors |
| NCT03937843 | PHASE2 | ACTIVE_NOT_RECRUITING | Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma |
| NCT06684327 | PHASE2 | RECRUITING | Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors |
| NCT06814496 | PHASE1/PHASE2 | RECRUITING | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors |
| NCT06866964 | PHASE2 | RECRUITING | A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy |
| NCT06932458 | PHASE2 | RECRUITING | A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases |
| NCT07407582 | PHASE1/PHASE2 | RECRUITING | Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) |
| NCT00042952 | PHASE2 | TERMINATED | Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer |
| NCT00183820 | PHASE2 | COMPLETED | Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma |
| NCT00467051 | PHASE2 | COMPLETED | Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors |
| NCT00531687 | PHASE2 | TERMINATED | Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer |
| NCT00587964 | PHASE2 | COMPLETED | Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases |
| NCT00772694 | PHASE2 | UNKNOWN | Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy |
| NCT00795769 | PHASE2 | COMPLETED | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
| NCT00936936 | PHASE2 | COMPLETED | High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors |
| NCT00957905 | PHASE2 | COMPLETED | Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors |
| NCT01037790 | PHASE2 | COMPLETED | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer |
| NCT01159067 | PHASE2 | TERMINATED | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload |
| NCT01242631 | PHASE2 | COMPLETED | Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer |
| NCT01684098 | PHASE2 | COMPLETED | Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor |
| NCT01808534 | PHASE2 | TERMINATED | Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors |
| NCT02478502 | PHASE2 | TERMINATED | Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer |
| NCT02643303 | PHASE1/PHASE2 | COMPLETED | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers |
| NCT02689219 | PHASE2 | TERMINATED | Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors |
| NCT02860819 | PHASE2 | COMPLETED | Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer |
| NCT03339635 | PHASE2 | COMPLETED | Short-term Testosterone Replacement in Testicular Cancer Survivors |
| NCT06515613 | PHASE1 | RECRUITING | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors |
| NCT06673329 | PHASE1 | RECRUITING | Brodalumab in the Treatment of Immune-Related Adverse Events |
| NCT07106827 | PHASE1 | RECRUITING | A Study of GV20-0251 in Advanced or Refractory Solid Tumors |
| NCT07218913 | PHASE1 | RECRUITING | Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors |
| NCT00004074 | PHASE1 | COMPLETED | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu |
| NCT00028496 | PHASE1 | COMPLETED | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer |
| NCT00060372 | PHASE1 | COMPLETED | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer |
| NCT00423254 | PHASE1 | COMPLETED | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. |
| NCT00638898 | PHASE1 | COMPLETED | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor |
| NCT01242072 | PHASE1 | UNKNOWN | Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 4 |
| 2-MERCAPTOETHANESULFONIC ACID | 4 | 2 |
| BLEOMYCIN SULFATE | 4 | 1 |
| BRENTUXIMAB VEDOTIN | 4 | 1 |
| CABAZITAXEL | 4 | 1 |
| DEFERASIROX | 4 | 1 |
| IMATINIB | 4 | 1 |
| METHADONE | 4 | 1 |
| PALBOCICLIB | 4 | 1 |
| TARLATAMAB | 4 | 1 |
| TESTOSTERONE | 4 | 1 |
| TREMELIMUMAB | 4 | 1 |
| VELIPARIB | 3 | 2 |
| PALIFOSFAMIDE | 3 | 1 |
| ALVOCIDIB HYDROCHLORIDE | 2 | 1 |
| EDODEKIN ALFA | 2 | 1 |
| HILTONOL | 2 | 1 |
| CHEMBL4746472 | 0 | 1 |